Otros idiomas NervGen Pharma Corp.

Acciones

NGEN

CA64082X2032

Diferido Toronto S.E. Otros sitios de cotización 21:36:31 02/05/2024			Varia. Cinco días.	Varia. 1 de enero.
2,2 ^CAD	+7,32 %		+6,80 %	-18,52 %

17/04	NervGen informa de una pérdida neta de 0,38 dólares por acción en el ejercicio fiscal 2023 y proporciona información actualizada sobre sus operaciones	MT
17/04	NervGen Pharma Corp. informa de los resultados del ejercicio finalizado el 31 de diciembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

NervGen Engages Russo Partners LLC to Provide Public Relations Services	25/04
NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update	17/04
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates	17/04
NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	17/04
Non-Opioid Revolution: Beacons of Hope in Opioid Crisis and a $50 Million Spin-Off	09/04
NervGen Pharma Closes C$23 Million Bought Deal Financing	28/03
NervGen Completes $23 Million Bought Deal Financing	28/03
Canadian Investment Regulatory Organization Trade Resumption - NGEN	21/03
NervGen Pharma Raising C$20.1 Million in Bought-Deal Offering of Share Units	21/03
NERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERING	21/03
Canadian Investment Regulatory Organization Trading Halt - NGEN	21/03
NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company	21/02
NervGen Pharma Grants Stock Options	20/02
NervGen Pharma Corp. Plans to Initiate A New Study in Which Subjects Completes Open-Label Nvg-291	15/02
NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury	15/02
NervGen Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
NervGen Pharma Reports Q3 2023 Financial Results and Operational Updates	09/11
Neuroscientist and NervGen Pharma Scientific Founder, Dr. Jerry Silver, Interviewed on 'Remarkable People' Podcast Hosted by Tech Luminary Guy Kawasaki	08/11
NervGen Pharma Corp. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury	23/10/23
NervGen Pharma Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury	23/10/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas NervGen Pharma Corp.

Acciones

NGEN

CA64082X2032

Otros idiomas

Filtros